文献速递心律失常心力衰竭与心肌病

房室结消融联合心脏再同步治疗对永久性房颤伴窄QRS患者的死亡率影响:APAF-CRT试验

AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial.
PubMed 文献 · Eur Heart J · 2021-01-01

APAF-CRT试验为国际开放标签盲法结局研究,纳入133例永久性房颤>6个月、窄QRS(≤110 ms)且近1年至少1次心衰住院的患者,随机比较房室结消融联合双心室起搏(Ablation+CRT)与药物心率控制。中位随访29个月时因疗效提前终止,主要终点全因死亡在Ablation+CRT组7例(11%)vs药物组20例(29%)(HR 0.26,95%CI 0.10-0.65;P=0.004),2年死亡率5% vs 21%,4年14% vs 41%。

要点

  • Ablation+CRT显著降低全因死亡(HR 0.26,95%CI 0.10-0.65;P=0.004)。
  • 全因死亡或心衰住院复合终点亦显著降低(HR 0.40,95%CI 0.22-0.73;P=0.002)。
  • 获益在EF≤35%和>35%患者中相似。

核心结论

  • 对于永久性房颤伴窄QRS且曾因心衰住院的患者,Ablation+CRT较药物心率控制降低全因死亡率。

研究设计与样本

  • 国际、开放标签、盲法结局的随机对照试验,共随机133例患者。
  • 入选标准:永久性房颤>6个月、严重症状、窄QRS(≤110 ms)、近1年至少1次心衰住院。
  • 随机分配至Ablation+CRT组或药物心率控制组。
  • 中位随访29个月时因疗效提前终止。

主要发现

  • 主要终点全因死亡:Ablation+CRT组7例(11%)vs药物组20例(29%)(HR 0.26,95%CI 0.10-0.65;P=0.004)。
  • 2年估计死亡率:Ablation+CRT组5% vs药物组21%;4年:14% vs 41%。
  • 次要终点全因死亡或心衰住院:Ablation+CRT组18例(29%)vs药物组36例(51%)(HR 0.40,95%CI 0.22-0.73;P=0.002)。
  • EF≤35%与>35%患者中Ablation+CRT对全因死亡的获益相似。

临床怎么用

  • 对永久性房颤伴窄QRS且曾因心衰住院、症状严重的患者,可考虑Ablation+CRT以降低死亡风险。
  • 基线EF≤35%或>35%均可考虑该策略。

局限性

  • 开放标签设计。
  • 样本量较小(133例),因疗效提前终止。
  • 随访时间有限(中位29个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: In patients with atrial fibrillation (AF) and heart failure (HF), strict and regular rate control with atrioventricular junction ablation and biventricular pacemaker (Ablation + CRT) has been shown to be superior to pharmacological rate control in reducing HF hospitalizations. However, whether it also improves survival is unknown. METHODS AND RESULTS: In this international, open-label, blinded outcome trial, we randomly assigned patients with severely symptomatic permanent AF >6 months, narrow QRS (≤110 ms) and at least one HF hospitalization in the previous year to Ablation + CRT or to pharmacological rate control. We hypothesized that Ablation + CRT is superior in reducing the primary endpoint of all-cause mortality. A total of 133 patients were randomized. The mean age was 73 ± 10 years, and 62 (47%) were females. The trial was stopped for efficacy at interim analysis after a median of 29 months of follow-up per patient. The primary endpoint occurred in 7 patients (11%) in the Ablation + CRT arm and in 20 patients (29%) in the Drug arm [hazard ratio (HR) 0.26, 95% confidence interval (CI) 0.10-0.65; P = 0.004]. The estimated death rates at 2 years were 5% and 21%, respectively; at 4 years, 14% and 41%. The benefit of Ablation + CRT of all-cause mortality was similar in patients with ejection fraction (EF) ≤35% and in those with >35%. The secondary endpoint combining all-cause mortality or HF hospitalization was significantly lower in the Ablation + CRT arm [18 (29%) vs. 36 (51%); HR 0.40, 95% CI 0.22-0.73; P = 0.002]. CONCLUSIONS: Ablation + CRT was superior to pharmacological therapy in reducing mortality in patients with permanent AF and narrow QRS who were hospitalized for HF, irrespective of their baseline EF. STUDY REGISTRATION: ClinicalTrials.gov Identifier: NCT02137187.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Brignole M, Pentimalli F, Palmisano P, et al. AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial. Eur Heart J. 2021. PMID: 34453840. doi:10.1093/eurheartj/ehab569

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。